Idoroenyi Amanam, M.D.

I believe in treating all my patients with compassion and utilizing intellectual curiosity to tailor my treatment approaches.Idoroenyi Amanam, M.D., is a triple-boarded physician with advanced fellowship training utilizing cellular and stem cell therapy to treat malignant conditions. Dr. Amanam obtained his medical degree from Meharry Medical College in Nashville, Tennessee. He completed his training at St. Mary-UCLA Internal Medicine Residency, where he was awarded Intern of the Year, Resident of the Year and Chief Resident distinctions. Following residency, Dr. Amanam completed his hematology and oncology training here at City of Hope/UCLA-Harbor combined program, serving as chief fellow. He was then awarded the prestigious City of Hope Hematopoietic Cell Transplantation and Cellular Therapy Fellowship, with a concentration on acute leukemias and myeloproliferative neoplasms. Dr. Amanam is multilingual (English, Ibibio, Efik) and was awarded a U.S. Congressional Award in service — he is motivated to carrying this to the clinic. He firmly believes in serving his patients and enjoys the time spent educating them and their families regarding specifics of their disease. Dr. Amanam believes he was chosen to enter this field as he had a loved one who struggled with cancer and lived years longer than expected thanks to compassionate care by the doctors and nurses. “That experience always left an impression with me,” he said. “I knew this was the only field for me.” Dr. Amanam focuses his research on leukemia, stem cell transplants and myeloproliferative neoplasms, when the body produces too many red or white blood cells. “(The) patients are humble,” he explained, “the disease profile is diverse and from a research perspective there is still room for improving outcomes.”

• Nafie E, Amanam I, Ghoda L, Glackin C, Marccuci G. Twisting Stemness in AML using Nanoparticles as a Delvery System for SiRNA Targeting Twist. (Pending Submission)
• Amanam I, Mei M, Gupta R, Pullarkat V. Immune mediated thrombocytopenia after Immunotherapy, A single center experience. (Pending Submission)
• Amanam I, Chlebowski, R, Nelson R, Mambetsariev I, Heymach J. Salgia R. Lung Cancer in African-Americans and analysis of estrogen plus progestin use based on ancestry. (Pending Submission)
• Amanam I, Mambetsariev I, Gupta R, Salgia R. Progressive Neurologic Changes in a Patient with Metastatic Non-Small Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis? Accepted for publication in JCO Oncology Practice. 2020 March.
• Amanam I, Mambetsariev I, Gupta R, Achuthan S, Wang Y, Pharaon R, Massarelli E, Koczywas M, Reckamp K, Salgia R. Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. Accepted for publication in Journal of Thoracic Disease. 2020 March.
• Gupta R, Othman T, Uche A, Amanam I, Chen C, Celles L, Lane G, Mei M, Aldoss I, Pullarkat V, Kim P. Characteristics and trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital. Clinical Lymphoma Myeloma and Leukemia. 2020 Feb 28.
• Mambetsariev I, Wang Y, Chen C, Nadaf S, Pharaon R, Fricke J, Amanam I, Amini A, Bild A, Chu P, Erhunmwunsee L. Precision medicine and actionable alterations in lung cancer: A single institution experience. PloS one. 2020 Feb 11;15(2):e0228188.
• Krishnan A, Nathwani N, Gupta R, Amanam I*. Multiple Myeloma. Oncology in the Precision Medicine Era. 2020 Jan.
• Afkhami M, Schmolze D, Yost SE, Frankel PH, Dagis A, Amanam I, Telatar M, Nguyen K, Yu KW, Luu T, Pillai R. Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. PloS one. 2019 Nov 6;14(11):e0224726.
• Amanam I, Koczywas M. Novel Therapies for Small Cell Lung Cancer. Targeted Therapies for Lung Cancer. 2019 Jun 26:163. Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R. Anaplastic Lymphoma Kinase (ALK)-positive Tumors. American journal of clinical oncology. 2019 Apr 1;42(4):337-44.
• Gupta R, Cristea M, Frankel P, Ruel C, Chen C, Wang Y, Amanam I, Koehler S. Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer treatment and research communications. 2019 Jan 1;21:100155.
• Hill A, Gupta R, Zhao D, Vankina R, Amanam I, Salgia R. Targeted Therapies in Non-small-Cell Lung Cancer. Cancer treatment and research. 2019;178:3.
• Amanam I. Lung Cancer. In: Menopause Practice: A Clinicians Guide. Pepper Pike, OH: The North American Menopause Society; 2019 Sep 25: 224-226.
• Amanam I, Gupta R, Mambetsariev I, Salgia R. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncology. 2018 Feb 16(00).
• Amanam I, Gupta R, Mita A, Scher K, Massarelli E. Perspectives in Head and Neck Medical Oncology. Cancer Treat Res. 2018;174:163-185.
• Sécher T, Guilleminault L, Reckamp K, Amanam I, Plantier L, Heuzé-Vourc’h N. Therapeutic antibodies: A new era in the treatment of respiratory diseases? Pharmacology & therapeutics. 2018 May 4.
• Amanam I, Chung V. Targeted Therapies for Pancreatic Cancer. Cancers. 2018 Jan 29;10(2):36. Gupta R, Amanam I, Chung V. Current and future therapies for advanced pancreatic cancer. Journal of surgical oncology. 2017 Jul 1.
• Chan JK, James SL, Gardner AB, Amanam I, Kapp DS. A Comparative Study of Minimally Invasive Versus Open Hysterectomy for Women With Fibroid Uterus–A Nationwide Study of 65,216 Patients. Journal of minimally invasive gynecology. 2015 Nov 1;22(6):S62